Drug Profile
Semapimod
Alternative Names: AXD-455; CN-1493; CNI 1493; CPSI-2364; Semapimod saltLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Picower Institute for Medical Research
- Developer Cytokine PharmaSciences; GPC Biotech AG
- Class Anti-inflammatories; Hydrazones; Small molecules
- Mechanism of Action Cytokine inhibitors; HIV replication inhibitors; Immunomodulators; Interleukin 1 inhibitors; Interleukin 6 inhibitors; Mitogen-activated protein kinase inhibitors; Nitric oxide inhibitors; Raf kinase inhibitors; RNA inhibitors; Tumour necrosis factor alpha inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
- Discontinued Chemotherapy-induced damage; Crohn's disease; HIV infections; Pancreatitis; Psoriasis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in USA (PO)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in USA (PO)
- 20 Oct 2011 Cytokine PharmaSciences has been acquired by Ferring Pharmaceuticals